 |
TSO3: New Sale of a 125L Ozone Sterilizer in the United StatesDecember 13, 2006Québec City, December 13, 2006 – TSO3 Inc. (“TSO3”) (TSX: TOS) announces another firm sale of the 125L Ozone Sterilizer to a hospital in the United States. Considered among the leaders in medical innovation, this university hospital is known for its heart and lung transplant program.Convinced of the benefits our technology provides, this hospital was particularly attracted to the ease of use for the 125L Ozone Sterilizer, as well as its environmental value and the savings it brings. “This additional direct sale is very promising and supports our choice of commercial strategy,” said Jocelyn Vézina, the Chief Executive Officer of TSO3 Inc. “Put into action early in the year, our sales force – who must deal with a purchasing cycle of more than 12 months – is beginning to reap the fruits of their labours.” “This sale and the others to come clearly illustrate the time required for the purchasing process of a capitalized device such as the 125L Ozone Sterilizer. That’s why, with the sales in the pipeline since the beginning of the year, we are confident we will see our sales increase in 2007. This important sale confirms once again the need in the market for technology such as ours: sterilization technology that is simple, safe, environmentally friendly and economical,” added Mr. Vézina. About TSO3 TSO3 Inc. is located in Québec City, Québec, Canada, and was founded in 1998. The Company’s mission is to develop and market innovative and comprehensive sterilization solutions. TSO3 has perfected an innovative sterilization process using ozone as the sterilizing agent. The first product based on this technological platform is the 125L Ozone Sterilizer, which is intended for hospital sterilization units. The 125L – named after its 125-litre/4.3-cubic-foot capacity – was designed to sterilize heat-sensitive surgical and diagnostic devices which are expensive and in high demand from the surgical suite. The ozone sterilization process is a safe, efficacious, fast and cost-effective response to evolving sterilization needs. The 125L Ozone Sterilizer by TSO3 has been cleared for commercialization by Health Canada and by the U.S. Food and Drug Administration (FDA). TSO3 completed the sale of its first sterilizer in Q4 2005. TSO3 currently has about 50 employees, 22 of whom work in the sales and marketing team. The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties. The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it. - 30 - Source: TSO3 Inc. Information: Mathieu Claise Interim Director, Corporate Communications and Investor Relations 418 651-0003, Ext. 237 Email: ir@tso3.com |
© 2005-2008 TSO3. All Rights Reserved.
